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Abstract 
Over the past decade, epigenetics has emerged as a new layer of regulation of gene expression. 
Several investigations demonstrated that nutrition and lifestyle regulate lipid metabolism by 
influencing epigenomic remodeling. Studies on animal models highlighted the role of epigenome 
modifiers in specific metabolic contexts and established clear links between dysregulation of 
epigenetic mechanisms and metabolic dysfunction. The relevance of findings in animal models has 
been translated to humans, as epigenome-wide association studies (EWAS) deeply investigated the 
relationship between lifestyle and epigenetics in human populations. In this review, we will provide 
an outlook of recent studies addressing the link between epigenetics and lipid metabolism, by 
comparing results obtained in animal models and in human subjects. 
 
Keywords: Epigenetics, chromatin, non-coding RNA, histones, lipid metabolism, nutrition 
 
1. Introduction 
All the living organisms constantly communicate with the environment. Both unicellular organisms 
and cells within a multicellular organism must be ready to adapt to several perturbations occurring 
in the external world (Turner 2009). The capacity to rapidly sense, integrate signals and elaborate a 
response is a signature of the plasticity and the robustness of a biological system (Kitano 2007). All 
the external stimuli and the environmental changes influence the cell behavior through the 
activation of specific cellular programs, resulting in rapid and stable alterations in gene expression. 
The epigenetic machinery plays an important role in the establishment of peculiar patterns of gene 
expression and hence in the regulation of physiological responses. Epigenetics include all the 
mechanisms that heritably change the transcriptome by modifying chromatin structure without 
variations in the DNA sequence (figure 1A). These mechanisms make DNA locally more packaged 
or accessible to transcriptional factors and RNA polymerases (i.e. eu-/heterochromatin 
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respectively). For this reason, chromatin is much more than a neutral system for packaging and 
condensing genomic DNA, but it is a highly dynamic platform that can be modified at different 
levels. The combination of different chromatin modifications constitutes the epigenetic code. 
 
1.1 DNA methylation 
The first layer of the epigenetic landscape architecture is DNA methylation: this covalent 
modification occurs at cytosine residues located at 5’ of guanine residues (“CpG islands”) and is 
mediated by DNA methyltransferase enzymes (Dnmt). In general, an exclusivity between active and 
“open” chromatin structures and DNA methylation exists (Weber et al. 2007). In fact, in 
mammalian genomes, the CG rich regions are prevalently unmethylated, for example high CpG-
content promoters (HCPs) activate the expression of genes essential for cellular functions and are 
active by default (i.e. housekeeping genes promoters). On the contrary, the CG poor chromatin, 
such as low CpG-content promoters (LCPs), is methylated and seems to be selectively activated, for 
example by specific transcription factors. 
 
1.2 Histone modifications  
The second layer of the epigenome architecture is the “histone code”, a combination of a variety of 
post-translational modifications of histones. In contrast to DNA that undergoes only methylation, 
histone tails can be modified by methylation, acetylation, phosphorylation, biotinylation, 
ubiquitination, sumoylation and ADP-ribosylation. Lysine residues in the histone tails can be either 
mono-, di- and tri- methylated or acetylated, meanwhile arginine residues can be only mono- or di-
methylated. The level of histone acetylation is regulated by histone acetyltransferases (HAT) and 
histone deacetylases (HDAC). In contrast, regulation of histone methylation relies on histone 
methyltransferases (HMT) and demethylases (HDM) (for a complete review refer to (Barth and 
Imhof 2010; V. W. Zhou, Goren, and Bernstein 2011; J. Zhou and Troyanskaya 2016).  
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The diverse combination of different histone modifications in the same locus can provide a 
particular output in term of modulation of gene expression. Among the most important histone 
marks associated with an active transcription there are histone 3 lysine 4 tri-methylation 
(H3K4me3) at promoters, histone 3 lysine 4 mono and di-methylation (H3K4me1/me2) and histone 
3 lysine 27 acetylation (H3K27ac) at enhancers, histone 3 lysine 36 tri-methylation (H3K36me3) 
and histone 3 lysine 79 tri-methylation (H3K79me3) along the gene bodies. On the contrary, among 
the most significant silenced chromatin marks there are histone 3 lysine 9 tri-methylation 
(H3K9me3), histone 3 lysine 27 di- and tri-methylation (H3K27me2/me3), histone 4 lysine 27 di- 
and tri-methylation (H4K27me2/me3) and histone 4 lysine 20 tri-methylation (H4K20me3).  
 
1.3 Non Coding RNAs (ncRNAs) 
Other important epigenetic regulators are non-coding RNAs (ncRNAs) (figure 1B) (for detailed 
review see Sadakierska-chudy & Małgorzata 2015). Among all, the class of long non-coding RNAs 
(lncRNAs > 200 nt in lenght) is the least characterized and their physiological role is still largely 
unknown. Recent investigations indicate that lncRNAs could play critical roles in essential 
physiological processes, such as nutrient sensing and maintenance of metabolic homeostasis. Most 
lncRNAs are localized in the nucleus and seem to be involved in the regulation of chromatin state. 
In fact, they can guide chromatin-modifying complexes to specific genomic loci and it has been 
demonstrated that lncRNAs recruit chromatin-remodeling complexes to specific chromatin loci 
(Moran, Perera, and Khalil 2012). 
Another class of ncRNAs is the one of microRNAs (miRNAs). They are small single stranded RNA 
with 18-25 nucleotides in length that regulate mRNA degradation or protein translation. miRNAs 
can positively or negatively regulate expression of target genes (Ambros, 2001, Lewis et al., 2003), 
by inhibiting translation or by increasing degradation of target mRNA. 
Epigenetic regulation mediated by miRNAs required the RNA-induced silencing complex (RISC), 
which is driven by miRNA on the target sequence via complementary base pairing. Interestingly it 
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has been demonstrated that aberrant expression of miRs correlates with the onset of several 
metabolic diseases, including obesity, insulin resistance, type 2 diabetes mellitus, and fatty liver 
disease (Lynn 2009; Hulsmans, Keyzer, and Holvoet 2016). Recently, many studies are combining 
these research areas to contribute to the advance of knowledge and, possibly, to identify new 
strategies of therapeutic intervention. 
 
1.4 Nutrients influence epigenetic control of gene expression 
It is now well known that epigenetic mechanisms not only regulate several important physiological 
processes such as embryonic development and aging, but they also play a central role in 
pathological processes such as cancer, inflammation, obesity, insulin resistance, type 2 diabetes 
mellitus, cardiovascular, neurodegenerative and immune diseases. It is likewise widely known that 
nutrients can modify pathophysiological processes by changing gene expression patterns through 
modifications of the epigenetic landscape resulting from alteration of metabolite levels (rev. in Lu 
& Thompson 2012; Katada et al. 2012; Keating & El-Osta 2015). At this regard, nutrients can 
influence epigenome either by directly regulating enzymes that catalyze DNA methylation or 
histone modifications or by altering the levels of metabolic intermediates necessary for enzyme 
reactions (Choi and Friso 2010; Jang and Serra 2014). In fact, all chromatin-modifying enzymes 
need coenzymes, such as ATP, Acetyl-CoA and S-adenosylmethionine (SAM) that function as 
phosphate, acetyl and methyl group donors. The level of these metabolites changes with the 
metabolism of energy-rich substrates such as carbohydrates and fatty acids present in diet 
(Martinez-Pastor, Cosentino, and Mostoslavsky 2013).  
An important class of enzymes whose activity is directly dependent from the energetic status of the 
cell is the class III HDACs, also known as sirtuins (SIRT) (for details see review articles Ferrari et 
al. 2012; Ye et al. 2016). Sirtuins are NAD+-dependent deacetylases, which cleave NAD+ to create 
an ADP-ribose acceptor for the acetyl group, and hence their activity is sensitive to changes in the 
intracellular NAD+/NADH ratio. Mammalian sirtuins have been connected to a wide range of 
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processes that encompass cellular stress resistance, genomic stability, tumorigenesis and they also 
play a central role in glucose and lipid metabolism (Finkel et al. 2009). 
Moreover, it has been observed that compounds such as folic acid, vitamin B-12, methionine, 
choline and betaine can affect DNA and histone methylation through altering the levels of SAM and 
S-adenosylhomocysteine, an inhibitor of methyltransferases (Mentch et al. 2015). Other water-
soluble B vitamins (i.e. biotin, niacin, and pantothenic acid) play important roles in histone 
modifications (Kirkland 2009): biotin is a substrate for biotinylation, niacin is involved in ADP- 
ribosylation (as a substrate of poly(ADP-ribose) polymerase) and in acetylation (as a substrate of 
Sirt1) and pantothenic acid is a part of Coenzyme A to form acetyl-CoA, the metabolic intermediate 
required for histone acetylation. Ethanol significantly affects one-carbon metabolism by limiting 
methyltransferases reactions (Kaminen-ahola et al. 2010). 
Furthermore, bioactive components of food can modify epigenetic phenomena through directly 
affecting enzymes involved in epigenetic mechanisms. For instance, genistein and tea catechin 
influence DNA methyltransferases (Dnmt) activity. Resveratrol, butyrate, sulforaphane, and diallyl 
sulfide inhibit HDAC and curcumin inhibits HAT (Nian et al. 2010; Chiu et al. 2009). 
 
1.5 Transgenerational epigenetic inheritance 
It has been suggested that a memory of former metabolic states exists and that transient changes in 
nutrition may have a long-lasting impact on gene expression (Vickers 2014), from previous 
generations and in particular from both mother and father (Woo and Patti 2008; Gluckman 2008; 
Ferguson-Smith and Patti 2011). The relevant aspect of paternal transmission is that sperm 
transmits only genetic and epigenetic factors, modeled by paternal diet, and that these spermal 
epigenetic perturbations transmitted to offspring influence adult metabolic phenotype.  
 
Given all these evidences, it is conceivable to envision that focused modulation of epigenetic 
mechanisms through diet or specific nutrients may prevent diseases and maintain healthy status. 
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In this review, we will focus on the role of epigenetics in the regulation of lipid metabolism in 
rodent models and in humans, highlighting the importance of epigenetic remodeling in the 
pathophysiology of metabolic disorders. 
 
2. Epigenetic regulation of lipid metabolism in rodents 
 
2.1 DNA methylation 
There are cumulating evidences that DNA methylation is susceptible to changes in environmental 
factors (Haan, Gevers, and Parker 1986; Henry et al. 1996; Staiger et al. 2006; Pogribny et al. 2006; 
Ghoshal et al. 2008). For example, the presence of hypermethylated CpG sites has been 
demonstrated upstream to TSS (transcription start site) of Pparg gene, the master regulator of 
adipogenesis, in visceral white adipose tissue (WAT) in response to high fat diet in mice (Fujiki et 
al. 2009).  
The genome wide study of Multhaup et al. showed 232 differentially methylated regions (DMRs) of 
the DNA correlated with diet in murine adipocytes (Multhaup et al. 2015). This study highlighted 
hypermethylated regions near genes involved in lipid metabolic pathways, whereas hypomethylated 
regions correlated with inflammatory/immune pathways. For example, in adipocytes from high-fat 
diet fed mice they found hypermethylation sites within the promoter of Pck1 gene encoding 
Phosphoenolpyruvate Carboxykinase, which catalyses the rate-limiting step in glyceroneogenesis in 
adipose tissue, a key pathway for fatty acids storage as triacylglycerols. Moreover, this study 
reported for the first time DMRs in Fasn gene encoding fatty acid synthase; these DRMs correlated 
with differences in terms of glucose tolerance test. Accordingly, there are several evidences 
indicating that de novo lipogenesis in adipose tissue is impaired during metabolic dysfunction and 
that restoring this pathway selectively in WAT could be a strategy to improve obesity-dependent 
insulin resistance (Cao et al. 2008; Roberts et al. 2009; Huo et al. 2012). Of note, these authors also 
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found that DMRs are conserved across species. In particular, the authors identified 625 genome-
wide DMRs in murine adipocytes that correlated with diet-induced obesity. Among these, 249 
DMRs presented conserved methylation changes in human obesity and 170 had the same direction 
of methylation changes in both species. Moreover, 30 of these DMRs overlapped with SNPs 
associated with human T2D genetic risk.  
Diet can also influence the transgenerational epigenetic inheritance, i.e. the transmission of 
phenotypic traits to the offspring via epigenetic modification in the germline (Daxinger and 
Whitelaw 2012) (Figure 2). Changes in DNA methylation level in the germline play a role in this 
mechanism. It has been clearly demonstrated that malnutrition during fetal life alters DNA 
methylation of specific genes and, as a consequence, increases the risk of developing obesity, 
insulin resistance in the following generation (Burdge et al. 2007). Recently, Martinez et al. 
(Martìnez et al. 2014) demonstrated that in utero undernutrition influences the lipogenic program in 
the liver of the second generation offspring, by reducing the expression of genes such as ATP-
citrate lyase (Acly), Fatty acid synthase (Fasn), Steroyl CoA desaturase 1 (Scd1), Elongase of very 
long chain fatty acid 6 (Elovl6) and Sterol-response element binding factor-1 (Srebf-1). This 
dysregulation is due, at least in part, to reduced expression of Liver x receptor α (Lxr-a or Nr1h3), 
the master regulator of the lipogenic program in the liver, which results from reduced DNA 
methylation level at CpG 5’ UTR promoter region and enrichment of repressive histone marks 
H3K9me2 and H3K27me3. This epigenetic signature was already present in sperm samples from 
their progenitors, meaning that it was inherited by somatic cells of offspring determining an altered 
metabolic phenotype. These mice showed moderated hypertriglyceridemia, increased hepatic 
cholesterol, increased VLDL production and reduced HDL cholesterol. Of note, this study 
highlighted how the peculiar combination of different epigenetic marks in a specific genetic locus 
determines the final molecular output in terms of gene expression.  
Methylation of both DNA and histones is catalyzed by enzymes that use intermediates and cofactors 
belonging to one-carbon metabolism: methionine, folate, choline and vitamin B12 are important 
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precursors of these pathways. It is well known that deficiency of these nutrients may lead to hepatic 
fatty acid accumulation (Zivkovic et al. 2009; Kajikawa et al. 2011). At this regard, it has been 
shown that supplementation with dietary methyl donors in high fat sucrose (HFS) fed Wistar rats 
reduced hepatic fat accumulation with decreased level of global DNA methylation in supplemented 
control fed animals (Cordero et al. 2013). In particular, the authors showed changes in DNA 
methylation profile at CpG sites of Sterol Regulatory Element Biding Protein 2 (Srebf2), 1-
acylglycerol-3-phosphate O-acyltransferase 3 (Agpat3), and Estrogen Receptor 1 (Esr1) promoters. 
Conversely, another study demonstrated that methionine restricted diets protects adult mice from 
age-related DNA hypomethylation in the liver. These investigators found increased hepatic global 
DNA methylation and reduced levels of S-adenosylhomocysteine (SAH), an important intermediate 
for DNA methylation reactions (Mattocks et al. 2016). These studies highlighted that diet may 
influence hepatic lipid metabolism by epigenetic control of gene expression. However, the opposite 
outcomes obtained in these studies highlights the need of more conclusive investigations to assess a 
possible link between methionine restriction and epigenetic regulation of lipid metabolism.  
 
2.2 Histone modifications 
Histone methylation is another epigenetic modification strictly linked with metabolism. It has been 
assessed that high fat diet (HFD) induces changes in chromatin methylation pattern, thus 
modulating the expression of genes involved in lipid metabolism. At this regards, Leung et al. 
(Leung et al. 2014) challenged C57BL/6J mice with HFD for 8 weeks and showed that HFD 
relaxed chromatin within cis-regulatory elements making them more accessible to transcription 
factors such as HNF4α (Hepatocyte Nuclear Factor 4α), FOXO1 (Fork-head box O1) and C/EBPα 
(CCAAT/enhancer binding protein α) in the liver. Moreover, they showed that chromatin sites, 
which upon HFD feeding become enriched in the activation histone mark H3K4me1 
(monomethylated lysine 4 of histone H3), adopt an open conformation increasing their accessibility 
to transcription factors. Interestingly, these changes in chromatin accessibility were mirrored by 
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more than 300 genes differentially regulated in mice fed HFD, most of which implicated in lipid 
metabolism. In another study, Jun et al. (Jun et al. 2012) showed an altered H3K4me3 and 
H3K9me3 profile in primary hepatocytes treated with fatty acids, an in vitro model resembling 
early stage of hepatosteatosis. In particular, they found that the presence of these histone marks in 
the Ppara promoter paralleled the reduced expression of PPARα and of other genes involved in 
lipid catabolism. Ppara encodes Peroxisome Proliferator-activated receptor α, a nuclear receptor 
that activates the lipid catabolic program. This suggests that fatty acid treatment in primary 
hepatocytes triggers the alteration of histone methylation profile of Ppara promoter that reduces its 
expression and contributes to lipid accumulation and exacerbation of hepatosteatosis. 
In 2009, two studies highlighted that the genetic ablation of H3K9-specific demethylase Jmjd1a, 
Jumonji domain containing 1A, induced metabolic impairment and obesity. Tateishi et al. (Tateishi 
et al. 2009) showed that mice lacking Jmjd1a developed obesity and hyperlipidemia in the 
adulthood. This was due to dysregulation of Ppara and Ucp1, two direct targets of Jmjd1a, in 
brown adipose tissue as a consequence of increased H3K9me2 levels at enhancers of these two 
genes. Moreover, they showed that Jmjd1a expression is induced upon β-adrenergic stimulation in 
brown adipose tissue (BAT). In addition, in the study of Inagaki et al. (Inagaki et al. 2009) the 
obese phenotype in Jmjd1a-/- mice correlated with reduced expression of several genes including 
those encoding the inhibitor of fat storage ApoC1, the insulin dependent glucose transporter Glut4, 
the anti-adipogenic transcription factor CoupTFII and Adamts9, which encodes a metalloprotease 
associated with type 2 diabetes. Recently, the same group disentangled the physiological role of 
Jmjd1a in the acute response to environmental factors, i.e. cold exposure, in brown adipose tissue. 
The authors demonstrated that Jmjd1a serves as a cAMP epigenetic sensor that induces a long-range 
looping of enhancer regions to transcription start site (TSS) to initiate transcription of thermogenic 
genes in BAT (Abe et al. 2015). In particular, they showed that Jmjd1a is phosphorylated at Ser265 
by PKA in response to β-adrenergic activation. As a consequence, Jmjd1a forms a complex with 
Swi/SNF proteins and PPARγ upon enhancers of thermogenic genes Adrb1 and Ucp1, which brings 
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enhancers in proximity of TSS of these genes thus stabilizing the recruitment of RNA pol II and 
inducing their transcription. This mechanism was independent from the demethylase activity of the 
protein. 
In a recent paper Mentch and colleagues (Mentch et al. 2015) showed that histone methylation 
dynamics senses rapid alterations in methionine metabolism. They found global alterations of 
histone methylation after methionine restriction in vitro and in vivo, with H3K4me3 levels being 
reduced within 2-4 hours after methionine deprivation. Since H3K4me3 marks active promoters, 
they evaluated also changes in gene transcription: one of the most down-regulated pathways was 
indeed a network of enzymes involved in one-carbon metabolism that showed reduced both 
H3K4me3 levels and mRNA levels. This suggested the inception of a feedback regulatory pathway 
to cope methionine restriction and maintain physiological homeostasis. Summarizing, this study 
demonstrated that cells could sense nutritional status and adapt to methionine restriction by 
modulating histone methylation levels and gene expression.   
A mechanistic explanation whereby lipid metabolism may modulate both DNA and histone 
methylation remains to be fully addressed: possibly lipid metabolism may regulate the activity of 
enzymes involved in methylation/demethylation and/or may alter the level of 
intermediates/cofactors involved in these pathways. At this regard, Teperino et al. (Teperino, 
Schoonjans, and Auwerx 2010) hypothesized a link between intermediate metabolism and the 
activity of LSD1 (Lysine Specific Demethylase 1): LSD1 catalyzes demethylation reactions by 
using FAD, a cofactor in reactions of fatty acid β-oxidation pathway (i.e., acyl-CoA 
dehydrogenase). 
 
A number of studies extensively demonstrated the tight link between histone deacetylases (HDACs) 
and metabolism. Several investigations dissected the role of specific histone deacetylases in the 
regulation of metabolism in specific tissues by using knock out murine models or chemical 
inhibitors (Chang et al. 2006; Potthoff et al. 2007; Knutson et al. 2008; Gao et al. 2009; Sun et al. 
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2011; Galmozzi et al. 2013). At this regard, Knutson et al. (Knutson et al. 2008) demonstrated that 
hepatic Hdac3 deletion disrupted normal regulatory networks and altered completely metabolic 
homeostasis causing hepatomegaly, hepatosteatosis and impairments of glucose and lipid 
metabolism. These alterations were due to activation of PPARγ regulatory network within the liver. 
Indeed, HDACs regulatory activity depends upon the co-recruitment of multi-protein complexes. 
For example, HDAC3 deacetylase activity requires interaction with corepressors Silencing 
Mediator for Retinoid and Thyroid Receptors (SMRT) and Nuclear Receptor Corepressor 
(NCoR1)(Guenther, Barak, and Lazar 2001; Yu et al. 2003). Moreover, it has been demonstrated 
that HDAC3 interact with MeCP2, Methyl-CpG-binding Protein 2 (Kyle et al. 2016). In this work 
the authors showed that hepatic ablation of MeCP2 caused dyslipidemia and non-alcoholic fatty 
liver disease (NAFLD) as a result of altered expression of genes involved in lipogenesis pathways. 
MeCP2 deletion, in fact, disrupts HDAC3 recruitment on specific loci and increased H3K27ac 
marks at the Squalene epoxidase (Sqle), Fatty acid synthase (Fasn), and Cluster of differentiation 36 
(Cd36) loci. The association of HDAC3 with hepatic genome is also regulated by the nuclear 
receptor Rev-erbα in a circadian fashion (Feng et al. 2011). During dark phase, when murine 
metabolism is active and in the feeding phase, low concentrations of Rev-erbα lead to dissociation 
of HDAC3 from the genome. Thus, acetylation levels at H3K9 are up-regulated during dark phase 
leading to increased expression in genes involved in hepatic de novo lipogenesis and this is reverted 
during light phase. Disruptions of this circadian mechanism lead to alteration in the epigenome that 
may contribute to the development of fatty liver. 
HDAC3 plays an important role in the regulation of lipid metabolism also in the heart. At this 
regard, Montgomery and coworkers (Montgomery et al. 2008) reported that cardiac specific 
ablation of Hdac3 upregulated expression of genes associated with an intense oxidative program 
(e.g., genes involved in fatty acid uptake, fatty acid oxidation, and electron transport chain/oxidative 
phosphorylation). These effects are related to hyperactivation of the nuclear receptor PPARα, 
which, together with HDAC3, forms a repressive complex on key target genes (Ucp2, Ucp3, Pdk4, 
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Acsl1, Fatp). However, Sun et al. (Sun et al. 2011) showed that Hdac3 cardiac-ablated mice 
exposed to high fat diet developed hyperthrophic cardiomyopathy, heart failure and lethality. In this 
experimental setting Hdac3 ablation was, in fact, accompanied by downregulation of genes 
involved in lipid catabolism and fatty acid oxidation, thus Hdac3 heart-specific knock out mice 
were not able to metabolize efficiently the dietary lipids and died from heart failure. This study 
demonstrated that HDAC3 transcriptionally regulates lipid catabolism in the heart and that loss of 
HDAC3 reduces the ability to respond to lipid overload, highlighting that high fat feeding reverts 
metabolic remodeling observed upon Hdac3 ablation in mice fed low fat diet (reported in 
Montgomery et al. 2008). 
Acetyl-CoA is as an important substrate of histone acetyltransferase (HAT) enzymes and represents 
the source of acetyl groups for histone acetylation (Wellen et al. 2009), indicating a link between 
metabolism and epigenetics. The nuclear ATP-citrate lyase (ACLY), the enzyme that converts 
citrate into acetyl-CoA and oxaloacetate, provides acetyl-CoA required to sustain histone 
acetylation. In the same study, these authors also demonstrated that reduced glucose concentration 
affected ACLY-dependent histone acetylation, thus suggesting that glucose metabolism is the major 
source of acetyl groups for acetylating chromatin.  
It would be interesting to verify whether, under particular metabolic conditions, lipid catabolism 
(i.e. fatty acid β-oxidation) could also be a source of acyl-CoA for chromatin acetylation.   
 
2.3 Non-coding RNA 
The discovery that non-coding RNAs (ncRNAs) account for almost two thirds of all transcripts 
raised interest in this fascinating mechanism of gene regulation. Some evidences support the 
possibility that long non-coding RNAs (lncRNAs) play a role in the regulation of lipid metabolism. 
At this regard, a liver-specific lncRNAs, named long non-coding liver-specific triglyceride 
regulator (lncSTR) (Li et al. 2015), whose expression is influenced by the nutritional status, has 
been identified.  Knock down of lncSTR  in vivo increased triglycerides clearance also in a setting 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
of hyperlipidaemia, the ApoE -/- mouse. The authors have also found that lncSTR is part of a 
molecular complex with TAR DNA binding protein 43 (TDP-43) that regulates the expression of 
Cytochrome P450 8b1 (Cyp8b1), a key enzyme in the bile acid synthesis pathway. This mechanism 
determines a specific bile acid pool that activates Farnesoid -X- receptor (FXR), which, in turn, 
induces apoC2 expression.  
Recently, Yang and colleagues used an integrated approach to identify 359 putative long non 
coding RNAs (lncRNA) that function as metabolic regulators in liver, adipose tissue and skeletal 
muscle (Yang et al. 2016). They found Gm16551, a liver-specific lncRNA strongly regulated by the 
master transcription factor of lipogenesis, SREBF1c. Liver-specific Gm16551 knock down mice 
showed increased expression of lipogenic genes Fasn, Acly and Scd1 and elevated circulating levels 
of triglycerides. 
miRNA is the family of ncRNAs better characterized and many investigators assessed their 
importance in the regulation of lipid metabolism. In vivo inhibition of miR-122, the predominant 
miRNA in the liver (Lagos-Quintana et al. 2002), reduced plasma cholesterol levels, hepatic fatty 
acid and cholesterol synthesis and enhanced hepatic fatty acid β-oxidation in lean mice (Esau et al. 
2006). miR-122 inhibition, in fact, decreased expression of genes involved in fatty acid synthesis 
such as Fasn, Acc1, Acc2, Scd1, and Acly. When fed high fat diet, mice treated with miR-122 
inhibitor showed decreased cholesterolemia and ameliorated liver steatosis with reduced levels of 
hepatic triglycerides. These results identified miR-122 as a regulator of cholesterol and fatty acid 
metabolism in the liver, suggesting it as an attractive therapeutic target for metabolic disorders.  In 
2010 Rayner et al. (Rayner et al. 2010) discovered miR-33 in an intronic sequence of SREBF2 
(Sterol Regulatory Element Binding factorr 2) gene, the master regulator of cholesterol 
homeostasis. This miRNA suppresses the expression of the cholesterol ATP-binding cassette A1 
(ABCA1) and other genes involved in cholesterol transport, thus reducing plasma levels of HDL-
cholesterol In a follow-up study the same group demonstrated that inhibition of miR-33 with 
antisense oligonucleotide reduced atherosclerotic plaques size in LDL-Receptor deficient mice, a 
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well-established model of atherosclerosis (Rayner et al. 2011). These oligonucleotides increased 
cholesterol efflux in the macrophages within the plaque, suggesting it as a promising strategy to 
treat cardiovascular disease.  
Moreover, it has been demonstrated that miR-33 has a central role in the cross talk regulation of 
cholesterol and fatty acid metabolism. SREBF1c, the hepatic regulator of de novo fatty acid 
synthesis,  is itself negatively regulated by miR-33 (Horie et al. 2013). mir-33-/- mice showed, in 
fact, increased body weight and hepatic steatosis due to increased expression of SREBF1 and its 
target genes, such as acetyl-CoA carboxylase (Acaca), fatty acid synthase (Fasn), Elongase of very 
long chain fatty acid 6 (Elovl6) and stearoyl-CoA desaturase (Scd1). These findings suggested that 
upregulation of miR-33 enhances cholesterol production in sterol depleted conditions. On the 
contrary, when cholesterol homeostasis is reached, decreased expression of miR-33 derepresses 
Srebf1 expression and consequently fatty acid synthesis is favoured. Another miRNA involved in 
the regulation of lipid metabolism is miR-335. miR-335 is up regulated in liver and white adipose 
tissue in different murine models of obesity including ob/ob, db/db, and KKAy mice (Nakanishi et 
al. 2009). 
Recently, it has been demonstrated that miRNAs could act in a concerted fashion to regulate lipid 
metabolism (Jeon et al. 2013). For example, mir-182 and miR-96 are expressed from the same 
polycistronic locus in response to transcription factor SREBP-2.  By acting as a “miRNA operon” 
this two miRNAs reduce the expression of F-box and WD-40 domain protein 7 (Fbxw7), and Insig-
2, insulin induced gene 2, respectively, two genes that negatively regulate SREBP2 by reducing its 
nuclear localization. 
 
3. Epigenetics of lipid metabolism in humans 
3.1 EWAS studies and DNA methylation 
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Animal studies provided important evidences about the role of epigenetics in the regulation of lipid 
metabolism and in the onset of metabolic diseases, paving the way for in depth analysis about the 
role of epigenetics in human metabolism. In the last few years, new multi-dimensional approaches 
have been used to understand how genetics and epigenetics interplay in pathophysiology of 
metabolic disorders. Giving the worrisome increase of obesity in western world, several studies 
focused their attention on epigenetics of metabolic alterations underlying obesity and overweight. It 
was demonstrated that the obesity risk allele FTO, encoding for Fat mass and obesity-associated 
protein also known as α-ketoglutarate-dependent dioxygenase, is associated with higher 
methylation of sites within intron one of the FTO gene, caused by CpG site creating SNPs (Bell et 
al. 2010). The authors described an interaction between genetic and epigenetic factors for the risk 
allele. More recently, a genome wide analysis on peripheral whole blood determined five sites, 
corresponding to six genes (KARS, TERF2IP, DEXI, MSI1, STON1 and BCAS3) that differ in 
methylation level between homozygous carriers of the normal and the risk allele of the FTO gene 
and twenty sites that correlate with obesity (Almén et al. 2012). In the last few years, deep 
investigations of epigenome in human populations have been performed and epigenome-wide 
association studies (EWAS) became a powerful instrument to investigate how profoundly dietary 
habits and lifestyle can contribute to epigenetic changes and how this rearrangement correlates with 
metabolic dysfunctions. Very large EWAS including 5465 subjects investigated the association of 
adiposity, defined by body mass index and waist circumference, and DNA methylation at numerous 
CpG sites in blood cells (Demerath et al. 2015). This study highlighted that several biological 
pathways are significantly enriched for methylation in association with obesity, including those 
involved in lipid and energy metabolism. Among the specific loci differentially methylated the 
authors reported carnitine palmitoyl transferase 1a (CPT1A, involved in mitochondrial uptake of 
long-chain fatty acids and triglyceride metabolism), ATP Binding Cassette Subfamily G Member 1 
(ABCG1, involved in macrophage cholesterol and phospholipids transport, and lipid homeostasis), 
and Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1, a key regulator of 
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lipogenesis). Another large-scale genome-wide analysis of the association between adult body mass 
index (BMI) and DNA methylation identified a correlation between BMI and methylation of a 
component of the hypoxia inducible transcription factor HIF3A, in blood and adipose tissue (Dick 
et al. 2014). This result is in line with other reports demonstrating that HIF system is involved in 
metabolic regulation and energy expenditure (Jiang et al. 2011). Recently, an association between 
adipose tissue DNA methylation and mRNA expression in human adipose tissue and three risk 
factors for metabolic diseases, i.e. age, BMI and HbA1c (a measure of long-term glycaemia) has 
also been shown (Rönn et al. 2015). The authors found significant correlations between age and 
methylation in CpG sites in genes involved in lipid metabolism, such as fatty acid elongase 2 
(ELOVL2) in both blood and adipose cells. Of note, this evidence highlights that blood-based 
epigenetic biomarkers mirror epigenetic signatures in metabolic tissues, suggesting that epigenetic 
marks may become interesting biomarkers of metabolic disorders in obesity, T2D and related 
diseases. The possibility of a rapid identification of these epigenetic biomarkers could allow a 
prompt and appropriate therapeutic intervention. Another important gene whose DNA methylation 
was increased in human adipose tissue and blood cells with increased age was Kruppel-like factor 
14 (KFL14). GWAS studies identified an association between SNPs near KFL14 and type 2 
diabetes and HDL cholesterol levels(Wang et al. 2014), further confirming the strict link between 
genetics and epigenetics in metabolic regulation, and providing new insights in the pathophysiology 
of obesity and related disorders. At this regard, Ahrens and co-workers (Ahrens et al. 2013) 
reported that non-alcoholic fatty liver disease (NAFLD), a pathologic condition associated to 
obesity, correlates with a peculiar hepatic methylation signature. The authors found NAFLD-
specific expression and methylation differences for genes regulating metabolism. Among these 
genes the authors identified ATP citrate lyase (ACLY). ACLY, catalysing the conversion of citrate 
into acetyl-CoA, is the first enzyme of fatty acid biosynthesis(Linn and Srere 1979) Non-alcoholic 
steatohepatitis determined decreased DNA methylation of ACLY gene, paralleled by higher ACLY 
mRNA expression, indicating activation of a lipogenic pathway in NAFLD patients. Moreover, the 
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authors compared liver biopsies before and after bariatric surgery and found that NAFLD-
associated methylation changes are partially reversible, demonstrating the possibility to remodel 
human epigenome through a therapeutic intervention. However, the possibility to selectively 
manipulate DNA methylation at specific epigenomic regions is a really challenging task, rather we 
envision the value of identifying differences in DNA methylation as useful biomarkers for the 
efficacy of pharmacological approaches in metabolic disorders. 
Another organ whose functionality is impaired in obesity is skeletal muscle. In skeletal muscle of 
obese patients the rate of fatty acid β-oxidation (FAO) is reduced (Kim et al. 2000), thus 
contributing to ectopic lipid accumulation. Maples et al (Maples et al. 2015) recently reported that 
blunted expression of carnitine palmitoyltransferase-1B (CPT1B) in primary human skeletal muscle 
cultures from obese women was accompanied by changes in CpG methylation. CPT1B mediates the 
transfer of long-chain fatty acids from the cytosol to the mitochondrial matrix and is a rate-limiting 
step in FAO. The authors found that, in response to a lipid overload, cell cultures from lean subjects 
showed increased expression of CPT1B, as result of reduced cytosine methylation in CPT1B 
promoter. In cells from obese patients this epigenetic remodelling is blunted, preventing the binding 
of key transcriptional activators such as peroxisome proliferator-activated receptor-δ (PPARδ) and 
hepatocyte nuclear factor 4α (HNF4α) to CPT1B promoter. 
Recently, an epigenome-wide association showed a correlation between obesity and deep changes 
in DNA methylation (Wahl et al. 2017) . The authors demonstrated these modifications occur as 
result of adiposity and they are not to  
be considered as the cause of obesity and related metabolic impairment. Interestingly from this 
study emerged the existence of sentinel methylation markers, associated to obesity, that determine 
gene expression signatures at specific loci, mostly corresponding to genes involved in lipid and 
lipoprotein metabolism, substrate transport and inflammatory pathways. The authors also 
demonstrated that alterations of DNA methylation profile on these loci could be predictive of the 
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future development of obesity-related disease, such as type 2 diabetes, paving the way for new 
prevention strategy for the onset of this pathology. 
All these experimental evidences demonstrate that DNA methylation profile strongly influences 
lipid metabolic pathways in several organs participating in energy homeostasis, and link 
indissolubly metabolic disorders and epigenome remodelling. 
It is important to notice that prenatal environment could influence DNA methylation. A study on 
Gambian pregnant women demonstrate that seasonal alterations in methyl-donor nutrient intake at 
the time of conception influences several plasma biomarkers predicting differential DNA 
methylation in lymphocytes and hair follicles obtained from infants postnatally(Dominguez-salas et 
al. 2014). Other authors investigated genome-wide DNA methylation on whole blood of adult 
offspring whose mothers were exposed to famine during the Dutch Hunger Winter (Heijmans et al. 
2008). This study highlighted that differential DNA methylation occurred only in subjects that were 
exposed to famine during early gestation (periconceptional exposure). Among the DNA regions 
differentially methylated, the authors identified genomic portion of INSR and CPT1A that were 
shown to have enhancer activity in vitro: differential methylation in these sites has been associated 
with birth weight and serum LDL-cholesterol. These results prove the link between the timing of 
nutritional challenges and epigenetic remodelling, which can alter metabolism. 
 
3.2 Histone modifications 
In analogy to evidences coming from studies in rodents, a link between metabolic disorders and 
histone modifications has also been demonstrated in humans. It has in fact been shown that global 
histone H3 methylation status changes in response to overweight: in particular the authors reported 
decreased lysine 4 dimethylation of histone H3 (H3K4me2) in adipocytes from diabetic and non 
diabetic obese subjects (Jufvas et al. 2013). On the other hand, they found that trimethylation of 
H3K4 (H3K4me3) was 40% higher in adipocytes from overweight diabetic subjects compared with 
normal-weight and overweight non-diabetic subjects. These results highlight that obesity and 
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diabetes correlates with altered histone methylation profile in adipocytes. Further epigenome wide 
studies with ChIP-seq are required to identify the differences in histone methylation in selective 
regions, to understand how histone methylation/demethylation is able to reprogram adipose tissue 
metabolism, identifying potential new regulatory circuits that could be exploited for the treatment of 
these disorders.  
Remarkably, histone modifications at very early stages of differentiation  determine long term 
rearrangement of metabolic signalling pathways. At this regard, Joseph and coworkers (Joseph et al. 
2016) mapped chromatin state for histone marks H3K27 acetylation (a mark of active chromatin) 
and H3K27 trimethylation (a repressing mark) in adipocytes obtained by differentiating 
mesenchymal stem cells (MSCs) from umbilical cord tissue of individuals who were born small for 
gestational age (SGA) or of normal neonates. Interestingly, it is known that SGA subjects have 
higher risk to develop metabolic diseases in the adulthood (Varvarigou 2010). Analysing these 
epigenetic modifications the authors were able to demonstrate that acyl-coenzyme A synthetase 1 
(ACSL1), which converts free long-chain fatty acids into fatty acyl-CoA esters (Soupene and 
Kuypers 2008), is associated with increased histone H3K27ac in adipocytes derived from MSCs 
obtained from SGA children. This evidence further demonstrated the existence of strict link 
between epigenetics and regulation of lipid metabolism in humans. Moreover, these results 
highlight that histones modifications occurring in cellular precursors could be maintained along 
differentiation phases, even when cells are cultured in vitro. 
Recent evidences demonstrated that histone modifications are important determinants also of 
hepatic metabolic signature: it has been shown that lysine-specific demethylase 2 (LSD2) regulates 
lipid metabolism in human hepatocytes (Nagaoka et al. 2015). The authors reported that LSD2, 
demethylating H3K4, is able to repress genes involved in lipid influx and metabolism, and that c-
Jun mediates recruitment of LSD2 on these genes. Interestingly they demonstrated that knock down 
of LSD2 increased intracellular levels of many lipid metabolites, thus determining higher 
susceptibility to cellular damage induced by exposure to free fatty acids. 
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3.3 microRNAs 
In recent years we have witnessed a growing interest in microRNAs in the pathophysiology of 
nonalcoholic steatohepatitis (NASH). Cheung and coworkers (Cheung et al. 2008), by comparing 
the expression of 474 human microRNAs in subjects with NASH versus controls (without lipid 
deposition in the liver), found that the expression of miR-122, the most abundant miRNA in the 
liver, was reduced in NASH. As a consequence of miR122 underexpression, the authors reported 
increased protein levels of its targets fatty acid synthase (FASN), 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase (HMG-CoA reductase) and their transcriptional activators, the sterol-
response-element-binding protein-1c and 2 (SREBP-1c, SREBP-2), which are involved in lipogenic 
pathways. This determines the ectopic lipid accumulation resulting in NASH. More recently, other 
authors identified 42 novel miRNAs differentially regulated in NAFLD as compared to non-
NAFLD liver (Soronen et al. 2016). PPARα/RXRα activation pathway was identified among the 
target pathways of these miRNAs. Indeed PPARα activates β-oxidation and it is known that its 
expression is reduced in NAFLD (Tyagi et al. 2011). Suppression of the PPARα/RXRα pathway by 
miRNAs reduces the rate of fatty acid oxidation, thus favouring lipogenesis and progression of liver 
disease. 
 
4. Conclusions 
The evidences from human and animal studies here reviewed (Figure 3) demonstrated that 
nutritional and lifestyle factors (both pre- and postnatal) impact epigenome remodelling, and finely 
regulate lipid metabolism. The study of epigenetic modifications related to metabolic pathologies in 
rodents is a valuable strategy in order to identify new targets for the treatment of human diseases. 
At this regard a similar DNA methylation pattern in murine and human obesity has been shown: to 
date 249 regions differentially methylated in animal and human studies have been identified, and 30 
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of these regions overlapped with SNPs associated to genetic risk to develop type 2 diabetes in 
human patients. Despite this overlapping, rodents and humans also showed different mechanism of 
regulation of lipid metabolism, since obesity in mice remodel DNA methylation upstream of Pparg 
gene and on Pck1 promoter, thus affecting glyceroneogenesis lipid and accumulation in WAT. 
Similar alterations have not been described in human WAT. On the other hand, in human 
adipocytes it has been proved a correlation between age and methylation at CpG sites in another 
gene playing key role in lipid metabolism, ELOVL2. Also, liver metabolism showed epigenetic 
regulation of some key actors in both mice and humans, even though this does not always occur 
through the same mechanisms; among these factors particularly relevant is the role of the lipogenic 
enzyme ATP citrate lyase (ACLY). The expression of this lipogenic gene in mouse liver is reduced 
upon maternal undernutrition, as a consequence of epigenetic switch off of Lxra gene. On the 
contrary, ACLY expression is induced through a reduction of DNA methylation status in human 
NASH. These evidences reveal a fine-tuning epigenetic regulation of ACLY, fundamental to 
maintain the balance of hepatic lipid metabolism. It is intriguing to notice that also other epigenetic 
mechanisms were conserved among species in the maintenance of lipid metabolism in liver. Among 
those a role is played by miR122, that was found to regulate lipid and cholesterol metabolism in 
murine models, but also resulted reduced in human NASH, arising as important modulator of lipid 
metabolism in human liver. 
This review highlighted that an important link between epigenetic regulation and metabolic health 
outcomes has been recognized, determining the upsurge of new interest in this field. The possibility 
to widely study epigenetic modifications through ChIP sequencing, together with the reduced cost 
of epigenome-wide association studies could allow bridging the observations coming from murine 
models in the context of human diseases. These investigations will shed new light in the knowledge 
of the strict link between epigenome, environment and metabolic pathologies, paving the way for 
new diagnosis and identification of novel potential therapeutic interventions. 
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Figure captions 
 
Figure 1 
Epigenetic mechanisms regulating genome function. (A) Environment influences chromatin state. 
Nutrients, life style and environmental stressors act as modulators of the epigenetic machinery, thus 
regulating the accessibility of DNA to transcription factors and RNA polymerase II, and 
establishing peculiar patterns of gene expression that are the results of a balance between activating 
and inhibiting DNA and histone modifications. (B) Furthermore, non-coding RNAs (ncRNAs), such 
as microRNAs (miRNA - 18-25 nt) and long non-coding RNAs (lncRNAs > 200nt), influence gene 
expression at the level of transcription or translation through the interaction with DNA and mRNA, 
and play a role in chromatin regulation by interacting with chromatin remodeling enzymes or 
transcription factors. 
 
Figure 2  
Transgenerational epigenetic inheritance. Environmental stimuli, such as lifestyle, exercise, smoke, 
etc. determine specific epigenomic patterns in the germline of an adult subject that could be 
transmitted to the offspring. This results in specific phenotypic traits such as predisposition to 
diseases that affect individuals in their entire life.  
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Figure 3  
Summary of the main epigenetic modifications described in the text correlated to environmental 
changes in mouse models and humans. 
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